Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
Biogen (BIIB) is undergoing a significant transformation, moving from an MS-focused company to a neuro-innovation powerhouse. Despite a challenging past with the Aduhelm controversy and patent cliffs, the company’s recent Q4 2025 earnings beat and aggressive 2026 guidance, driven by new treatments like Leqembi and Skyclarys, suggest a positive outlook under CEO Christopher Viehbacher’s leadership. The company faces competition and regulatory hurdles but aims for growth through strategic partnerships, acquisitions, and a pipeline focused on neurodegenerative and rare diseases.